Search Results

You are looking at 21 - 30 of 309 items for :

Clear All
Full access

Presenter : Shaji K. Kumar

Therapeutic advances have led to prolonged survival in multiple myeloma (MM), but it remains a chronic disease. The addition of several new therapies for both newly diagnosed and relapsed disease has also added complexity to treatment algorithms

Full access

Ashley T. Freeman, May Kuo, Lei Zhou, Justin G. Trogdon, Chris D. Baggett, Sascha A. Tuchman, Thomas C. Shea and William A. Wood

–outcome relationship in multiple myeloma (MM) showing that patients treated at low-volume facilities had a 22% increased risk of death compared with those treated at high-volume facilities. Provider expertise and hospital volume are overlapping, but both these distinct

Full access

Ashraf Badros

Multiple myeloma (MM) is a clinically and pathophysiologically heterogeneous disease, as evidenced by variable response to treatment and variation in survival from a few months to more than 10 years. Nationwide U.S. data show that approximately 20

Full access

Siyang Leng, Yizhen Chen, Wei-Yann Tsai, Divaya Bhutani, Grace C. Hillyer, Emerson Lim, Melissa K. Accordino, Jason D. Wright, Dawn L. Hershman, Suzanne Lentzsch and Alfred I. Neugut

Multiple myeloma (MM) is a hematologic malignancy characterized by significant bone disease; lytic lesions are present in >60% of patients at diagnosis, as are pathologic fractures, osteoporosis, and hypercalcemia. 1 Due to the frequency and

Full access

Paul G. Richardson, Jacob P. Laubach, Robert L. Schlossman, Constantine Mitsiades and Kenneth Anderson

Peripheral neuropathy (PN) and asthenia (fatigue) are among the most commonly seen complications in patients undergoing multiple myeloma (MM) therapy. These potentially debilitating adverse effects are frequently dose limiting, and they may

Full access

Shaji K. Kumar

Treatment Options for Myeloma Now Categorized The predominant change to the NCCN Guidelines for Multiple Myeloma (MM) is the grouping of treatment regimens according to “preferred,” “other,” and “useful in certain circumstances,” according to

Full access

NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020

Featured Updates to the NCCN Guidelines

Shaji K. Kumar, Natalie S. Callander, Jens Hillengass, Michaela Liedtke, Muhamed Baljevic, Erica Campagnaro, Jorge J. Castillo, Jason C. Chandler, Robert F. Cornell, Caitlin Costello, Yvonne Efebera, Matthew Faiman, Alfred Garfall, Kelly Godby, Leona Holmberg, Myo Htut, Carol Ann Huff, Yubin Kang, Ola Landgren, Ehsan Malek, Thomas Martin, James Omel, Noopur Raje, Douglas Sborov, Seema Singhal, Keith Stockerl-Goldstein, Carlyn Tan, Donna Weber, Alyse Johnson-Chilla, Jennifer Keller and Rashmi Kumar

be able to: Integrate into professional practice the updates to the NCCN Guidelines for Multiple Myeloma Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Multiple Myeloma Disclosure of Relevant Financial

Full access

Stephanie J. Lee

. Treatment of multiple myeloma . Blood 2004 ; 103 : 20 – 32 . 3 Hayashi T Hideshima T Anderson KC . Novel therapies for multiple myeloma . Br J Haematol 2003 ; 120 : 10 – 17 . 4 Maloney DG Molina AJ Sahebi F . Allografting with

Full access

Noopur S. Raje, Andrew J. Yee and G. David Roodman

The past 2 decades have seen remarkable advances in the treatment of multiple myeloma (MM). These advances began with the use of high-dose melphalan and autologous stem cell transplant 1 followed by the introduction of immunomodulatory drugs

Full access

Sagar Lonial and Jesus F. San Miguel

The treatment approaches, goals of therapy, and underlying philosophy for how to approach the treatment of a patient with newly diagnosed myeloma have dramatically shifted over the past 20 years. This shift has occurred partly as a consequence of